Aduro BioTech, Inc.
(NASDAQ : ADRO)

( )
ADRO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.11%62.180.0%$1999.69m
REGNRegeneron Pharmaceuticals, Inc. -2.18%599.472.5%$1212.04m
GILDGilead Sciences, Inc. -3.43%75.161.0%$972.03m
NVAXNovavax, Inc. 14.73%52.82102.0%$711.68m
AMGNAmgen, Inc. -1.22%226.911.3%$619.06m
VRTXVertex Pharmaceuticals, Inc. -0.46%286.641.9%$592.02m
BIIBBiogen, Inc. -1.84%301.451.6%$385.60m
ILMNIllumina, Inc. 0.65%365.413.5%$384.25m
SRNESorrento Therapeutics, Inc. -0.99%5.001.8%$320.03m
ALXNAlexion Pharmaceuticals, Inc. -0.82%118.922.0%$296.17m
SGENSeattle Genetics, Inc. 1.15%159.026.1%$258.80m
AAgilent Technologies, Inc. 2.01%89.911.6%$212.68m
BMRNBioMarin Pharmaceutical, Inc. 0.79%107.394.3%$185.56m
MGNXMacroGenics, Inc. 9.67%21.106.2%$174.18m
INCYIncyte Corp. -0.16%101.752.5%$166.58m

Company Profile

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.